Dr Krell MBChB BSc MRCP DPhil is a consultant oncologist, specialising in gastro-oesophageal, colorectal, pancreatic, liver and bile duct cancers and neuro-endocrine tumours. He is experienced in using chemotherapy, targeted therapy and immunotherapy. He also manages patients with cancer of unknown primary.

Dr Krell works as a member of the multidisciplinary team for gastro-oesophageal and hepatobiliary cancer at the Royal Free London and is also the clinical lead for neuro-endocrine tumour oncology at the Royal Free Hospital.



GMC number


• Multi-Centre randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma. PLOS ONE May 2016. Brown N, McBain C, Nash S, Hopkins K, Sanghera P, Saran F, Phillips M, Dungey F, Krell D, Jeffries S, Khan I, Smith P, Mulholland P.
• HOT mutation screening in human glioblastoma. Future Science OA, FSO22, DOI: 10.4155/FSO.15.20 (2015). Krell D, Mulholland P, Stebbing J, Tomlinson I, Bardella C.
• AT-43* Multi-centre, randomised double-blind phase II study comparing Cediranib (AZD2171) plus gefitinib (Iressa, ZD1839) with cediranib plus placebo in subjects with recurrent/progressive glioblastoma. Neuro-oncology 16: V8-22. 2014. Doi:10.1093/neuonc/neu237. Mulholland P, Krell D, Khan I, McBain C, Patel C, Wanek K, Hopkins K, Jeffries S, Jager R, Smith P, Liu Q, Stupp R, Tomlinson I.
• microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. Eur J Cancer. 2015 Jul; 51(11):1389-404. Frampton AE, Krell J, Jamieson NB, Gall TM, Giovannetti E, Funel N, Mato Prado M, Krell D, Habib NA, Castellano L, Jiao LR, Stebbing J.
• IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. Future Oncol. 2013 Dec; 9(12): 1923-35. Krell D, Mulholland P, Frampton AE, Krell J, Stebbing J, Bardella C.
• The Malignant Truth. Lancet Oncol. 2013 Jan;14(1): 25-6. Krell D, Stebbing J. Aristolochia:
• Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways. Expert Rev Anticancer Ther. 2012 Oct;12(10): 1275-8. Frampton AE, Krell J, Giovannetti E, Krell D, Stebbing J, Castellano L, Jiao LR.
• Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma. PLoS One. 2011; 6(5): e19868. Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C.
• A Retrospective Analysis of Primary Tumour Histology and Survival in Breast Cancer Patients Developing Symptomatic Brain Metastases Treated with Whole Brain Radiotherapy (WBRT) at Mount Vernon Cancer Centre (MVCC). Cancer Research: 2009 Dec; Vol 69, Issue 24, Supplement 3
• What is the evidence for rechallenging with anthracyclines or taxanes in metastatic breast cancer- A review of the data. J Clin Oncol 27:15s, 2009 (suppl; abstr 1072). Krell J, Harper-Wynne C, Miles D, Misra V, Cleator S, Krell D, Palmieri C.
• Impact of the effective prevention and management of febrile neutropaenia. Br J Cancer. 2009 Sep;101 Suppl 1:S23-6. Krell D, Jones A.

DPhil in clinical medicine obtained from the Wellcome Trust Centre for Human Genetics, University of Oxford. Establishing links between genetic mutations in genes involved in cellular metabolism and the development of cancer. Involvement in clinical trials of new therapies for gastrointestinal and hepatobiliary cancers.